Product name as reported
Bydureon Bcise: adverse event reports filed with FDA
12,882 reports list it as a suspect or interacting product, 2010–2026.
- 12,882
- reports as suspect product
- 0.1% of all reports · about 793 a year
- 21
- reports, 12 months to June 2026
- 610 in the 12 months before
- 10.8%
- marked serious by the reporter
- 57.4% across all reports
- 0.9%
- record death among outcomes, as reported
- 114 reports · not verified by FDA
12,882 adverse event reports received by FDA list the product name "Bydureon Bcise" as reporters wrote it as a suspect or interacting product, from April 2010 to April 2026. A further 216 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 21 reports listed it, down 97% from 610 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 793 reports a year and 0.1% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are device leakage (35.7%), injection site haemorrhage (26.7%) and incorrect dose administered by device (22.8%). A report can list several reactions, so shares add to more than 100%; 707 different terms appear across these reports. Device leakage is recorded in 35.7% of these reports, against 0.2% of all reports in the database.
10.8% of the reports are marked serious by the reporter; 0.9% record death among the outcomes and 3.2% record hospitalisation, as reported. 80.7% of the reports came from consumers, and the largest patient age group is 65 to 74 (23.2%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Bydureon Bcise reports recording the termall reports in the database
- Device leakagethe device leaked35.7%4,594
- Injection site haemorrhagebleeding where the injection was given26.7%3,440
- Incorrect dose administered by devicethe device gave the wrong dose22.8%2,941
- Wrong technique in device usage process20.3%2,621
- Injection site painpain where the injection was given18.9%2,429
- Device malfunctionthe device did not work properly17.3%2,231
- Device issuea problem with the device15%1,932
- Injection site mass14%1,804
- Device delivery system issuea problem with the delivery system11.3%1,461
- Needle issuea problem with the needle10.2%1,320
- Injection site extravasation10%1,285
- Blood glucose increasedraised blood sugar reading8.4%1,084
- Product dose omission issuea dose was missed7%898
- Device use issue6.9%883
- Incorrect dose administeredthe wrong dose was given6.6%848
- Injection site nodule6.3%813
- Weight decreasedweight loss6.2%799
- Intentional device misuse5.9%763
- Injection site bruisingbruising where the injection was given5.5%709
- Product dose omissiona dose was missed4.2%544
- Wrong technique in product usage processthe product was used in the wrong way4.1%522
- Injection site pruritusitching where the injection was given3.8%488
- Nauseafeeling sick3.4%444
- Intentional product misusedeliberate use not as intended3.2%413
- Injection site erythemaredness where the injection was given3.1%397
- Glycosylated haemoglobin increaseda raised HbA1c, the long-term sugar measure3.1%396
- Product use issuea problem in how the product was used2.8%367
- Circumstance or information capable of leading to medication errora situation that could lead to a medication error2.6%335
- Drug delivery system issue2.4%310
Top 30 of 707 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.9% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Type 2 diabetes mellitus | 5,872 | 45.6% |
| Diabetes mellitus | 2,067 | 16% |
| Glycosylated haemoglobin increased | 176 | 1.4% |
| Blood glucose abnormal | 170 | 1.3% |
| Blood glucose increased | 133 | 1% |
| Glucose tolerance impaired | 76 | 0.6% |
The indication field is filled in by the reporter and is often blank; shares are of all 12,882 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Bydureon Bcise reports |
|---|---|---|
| Bydureon | 2,609 | 20.3% |
| Metformin | 1,702 | 13.2% |
| Byetta | 467 | 3.6% |
| Lisinopril | 408 | 3.2% |
| Atorvastatin | 332 | 2.6% |
| Lantus | 329 | 2.6% |
| Aspirin | 306 | 2.4% |
| Farxiga | 257 | 2% |
| Jardiance | 257 | 2% |
| Insulin | 254 | 2% |
Other products listed in reports where Bydureon Bcise is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Bydureon Bcise | All reports |
|---|---|---|
| Reports as suspect product | 12,882 | 20,646,523 |
| Share of that pool | — | 0.1% |
| Reports, latest 12 months | 21 | 1,332,454 |
| Marked serious | 10.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 9 | 91 |
| Hospitalisation recorded, per 1,000 reports | 32 | 213 |
| Consumer-filed share | 80.7% | 45.8% |
| Top term, share of reports | Device leakage 35.7% | 0.2% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Bydureon Bcise reports
How many adverse event reports has FDA received for Bydureon Bcise?
12,882 reports list Bydureon Bcise as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 21 of them arrived in the latest 12 months. Another 216 list it only as a concomitant medication.
What reactions are recorded in Bydureon Bcise reports?
device leakage (35.7%), injection site haemorrhage (26.7%), incorrect dose administered by device (22.8%), wrong technique in device usage process (20.3%) and injection site pain (18.9%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Bydureon Bcise was responsible.
How serious are the reports?
10.8% are marked serious by the reporter. Among the outcomes recorded, 0.9% of reports include death and 3.2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (80.7%), not given (9.1%) and physician (6.1%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Bydureon Bcise rising?
21 reports in the 12 months to June 2026, down 97% from 610 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Bydureon Bcise was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Bydureon Bcise?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Bydureon Bcise as a suspect or interacting product; reports listing it only as a concomitant medication (216) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.